Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of June:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of May:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of April:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February:

Pharming Group N.V. announces 14 poster presentations by the Company or its collaborators regarding leniolisib and RUCONEST® at the International Primary Immunodeficiencies Congress (IPIC) and the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in November.

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conference in the month of November:

Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the U.S. in the month of September:

Pharming Group N.V. announces that Pharming’s management will attend the following investor conferences in the month of June:

Pharming Group N.V. announces that Pharming’s Chief Executive Officer, Sijmen de Vries will attend the H.C. Wainwright BioConnect Investor Conference 2023 on May 2, 2023 in New York and will take part in a fireside chat at 11:00 ET/17:00 CEST.